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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: To identify the prognostic factors for locally advanced cervical cancer
patients treated by intensity-modulated radiotherapy (IMRT) and concurrent cisplatin-based
chemotherapy.
Methods: A total of 125 patients with stage IB2eIII cervical carcinoma were treated with IMRT
and concurrent cisplatin-based chemotherapy, plus high dose rate (HDR) brachytherapy
between January 2004 and November 2010, in our institution. All patients received external irra-
diation of 45e54 Gy with the IMRT technique and concurrent cisplatin-based chemotherapy
monthly or weekly. HDR brachytherapy of 20e30.5 Gywas prescribed to point A, as a local boost.
Prognostic factors including age, histology, stage, lymph nodes metastasis, pretreatment hemo-
globin level, serum squamous cell carcinoma antigen (serum SCC-Ag), chemotherapy regimens
and the cumulative dose of weekly cisplatin, were analyzed. The endpoints were overall survival
(OS), local failure-free survival (LFFS) and disease-free survival (DFS).
Results: The median follow-up time was 42 months. The 4-year OS, LFFS and DFS were 73.8%,
77.9% and 67.2%, respectively. Four (3.2%) patients developed grade 3 acute gastrointestinal
(GI) toxicity and 29 (23.2%) patients developed grade 3 acute hematological toxicity. Five
(4.0%) patients developed grade 3 late GI toxicity and seven (5.6%) patients developed grade
3 late genitourinary system toxicity. On univariate analysis, adenocarcinoma was a poor prog-
nostic factor for OS (p Z 0.05), LFFS (p Z 0.01) and DFS (p Z 0.006). Patients with lymph
nodes metastasis at diagnosis had worse OS (pZ 0.02). The high cumulative dose of cisplatin
(>180 mg/m2) had better OS (pZ 0.03) and tended to have better survival on LFFS (pZ 0.13)
and DFS (pZ 0.10). On multivariate analysis, adenocarcinoma was a significant independentof Radiation Oncology, Taichung Veterans General Hospital, Number 160, Chung-Kang Road, Section
.com (L. Wang).
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232 C.-C. Chen et al.prognostic factor for OS (pZ 0.001), LFFS (pZ 0.005) and DFS (p < 0.001). Initial lymph nodes
metastasis was an independent predictor of OS (pZ 0.013). Cumulative dose of weekly cisplatin
significantly affectedOS (pZ 0.041), and high cumulative dose of cisplatin tended to have better
LFFS (pZ 0.083). Higher pretreatment hemoglobin level had better LFFS (pZ 0.034).
Conclusion: Adenocarcinomaand lymphnodesmetastaseswerepoorprognostic factors forpatients
with locally advanced cervical cancer. Lower pretreatment hemoglobin level had poorer local
control. Chemotherapy with a high cumulative dose of cisplatin tended to result in better survival.
Copyrightª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Five randomized studies1e5 demonstrated that concurrent
chemoradiotherapy (CCRT) improved overall survival (OS)
and progression-free survival in patients with locally
advanced cervical cancer. The use of radiotherapy with
concurrent cisplatin-based chemotherapy has become the
mainstay treatment in locally advanced cervical cancer.
Previous studies6,7 on other pelvic malignancies found
that intensity-modulated radiation therapy (IMRT) helped to
achieve adequate target organ and lymph nodes coverage
and decreased the dose to the small bowel, bladder and
rectum. Traditional radiation therapy techniques, including
three-dimensional conformal radiation therapy (3DCRT)
with uniform radiation intensity and/or with simple beam
fluence modifying devices, such as wedges, do not provide
a method for sparing critical structures that push into and
are partially or fully surrounded by a target or combination
of targets. IMRT dose plan and treatment delivery used
inverse or forward planning techniques for modulated beam
delivery, and used a binary collimator, orwith a conventional
multileaf collimator (MLC) system, either sliding window
(dynamic MLC) or step and shoot (segmented MLC) modes.
IMRT had more conformal dose distributions of the radiation
fields and reduction in the volume of critical organs. These
advantages may diminish acute and late toxicity. However,
the IMRT treatment had a longer treatment time than
conventional radiotherapy and the possibility of organ
motion. In our study,8 we demonstrated that IMRT achieved
good outcomes and was well tolerated, with favorable acute
and late toxicity in locally advanced cervical cancer
patients. In this retrospective study, we reviewed more
patients and all patients received IMRT and high dose rate
(HDR) brachytherapy; patients also had a longer follow up
time. One purpose of our study was to demonstrate the
longer treatment outcomes, including survival and toxicity,
of IMRTwith concurrent chemotherapy.
Many studies9e15 have shown that some prognostic
factors, such as concurrent cisplatin dose, histology,
advanced stage, age, and anemia, have an effect on
survival. Another purpose of this study was to identify the
prognostic factors of cervical cancer and find the patients
who need more aggressive treatment.
Methods and materials
Patients
A total of 125 stage IB2-III cervical cancer patients met the
inclusion criteria, which were: (1) biopsy confirmation ofadenocarcinoma or squamous cell carcinoma (SCC) of the
cervix; (2) no evidence of distant metastasis initially; (3)
completion of IMRT and concurrent cisplatin-based
chemotherapy plus HDR brachytherapy boost; and (4) no
previous surgery, chemotherapy or radiotherapy. All
patients received definitive CCRT at the radiation oncology
department of Taichung Veterans General Hospital in
Taiwan, between January 2004 and November 2010. The
pretreatment staging workup included a comprehensive
medical history, clinical physical examination, bimanual
pelvic and rectal examinations, cervical biopsy, a chest
X-ray, diagnostic abdomen and pelvic computed tomog-
raphy (CT) scan, complete blood cell count, blood chem-
istry profiles and serum SCC antigen (serum SCC-Ag). A
positron emission tomography (PET) scan was elective for
20 patients with equivocal lymph node metastasis at CT
scan. Magnetic resonance imaging was used for workup in
two selected patients. The lymph node metastasis criteria
including: (1) enlarged lymph node 0.8 cm and/or central
necrosis on CT scan; (2) 2-deoxy-2-fluoro-D-glucose (FDG)
increased uptake in the PET scan and compatible with the
equivocal lymph node region by CT scan; and (3) the
enlarged lymph node 0.8 cm and/or heterogeneous
enhanced signal intensity on T1-weighted image, were
considered as having clinical lymph node metastasis.
Cystoscopy or proctoscopy was indicated if bladder or
rectal invasion was suspected clinically. Clinical staging was
defined according to the International Federation of
Obstetrics and Gynecology (FIGO) staging system. Written
informed consent was obtained from each patient before
treatment. The study was approved by the Institutional
Review Board at Taichung Veterans General Hospital.IMRT technique and brachytherapy
All patients were scheduled to undergo IMRT and HDR
intracavitary brachytherapy. The treatment planning system
of Eclipse (Varian Medical Systems, Palo Alto, CA, USA)
software program was used for treatment planning of IMRT.
The IMRT treatment planning was delivered using a dynamic
multileaf linear accelerator with photon energy of 10 MV. In
general, a vacuum fixed pad was used to immobilize the
patient and bladder filling was arranged before taking a CT
image and daily treatment. The contrast-enhanced CT scan
images were obtained using a radiopaque marker, to define
the cervix and upper vagina before contouring. We checked
the patients’ position and V-films before IMRT treatment. If
the patients could not fit the vacuum fixed pad, we would
recheck the treatment centers and/or arrange repeat CT
images and another IMRT plan.
Table 1 Patient characteristics (n Z 125).
No. of
patients
Age <54 y 58
54 y 67
Histology Adenocarcinoma 20
Squamous cell
carcinoma
105
Grade 3 77
1 and 2 48
Tumor size 4 cm 52
>4 cm 73
Clinical
lymph node
metastasis
Negative 94
Pelvic node only 13
Para-aortic and/
or pelvic node
18
FIGO stage IB2 6
IIB 70
IIIA 5
IIIB 44
Serum SCC <2 ng/mL 29
2 ng/mL 76
Pretreatment
hemoglobin
level
11 g/dL 89
<11 g/dL 36
Radiotherapy
field
Pelvis 107
Extended field 18
Point A dose 7440 cGy 58
>7440 cGy 67
Chemotherapy Monthly 28
Weekly 97
Cumulative dose
of weekly
cisplatin
180 mg/m2 50
>180 mg/m2 47
Prognostic factors for cervical cancer patients 233Gross tumor volume (GTV) was defined as the cervix
tumor and uterus. GTV-N was defined as pelvic lymph nodes
0.8 cm. The clinical target volume (CTV) of IMRT covered
the pelvis and generally included a 0.5e1 cm margin to GTV
radially, the upper half of the vagina, the parametrium and
regional lymph nodes. The regional lymph nodes targeted
by IMRT included the common iliac, internal iliac, external
iliac and presacral area lymph nodes. The treatment field
extended from the L4e5 interspace to 3 cm below the most
distal vaginal or cervical site of disease. For 18 patients
with enlarged para-aortic lymph nodes, the superior field
border extended to the T12eL1 interspace. The CTV of
para-aortic lymph nodes included enlarged para-aortic
lymph nodes, plus a 0.5e1 cm margin radially and the
vascular structures such as aorta and inferior vena cava.
The planned target volume (PTV) with a 0.7e1 cm margin
superiorly, inferiorly,and radially,wasgiventotheCTV.A total
radiation dose of 50.4e54 Gy, 1.8 Gy/fraction, five fractions/
week, was delivered to the GTV. GTV-N used a concomitant
IMRT boost to 54e60 Gy to the involved lymphnodes. A dose of
45e48 Gy in 28e30 fractions was given to the CTV.
The dose constraint of normal tissues included the
bladder, rectum and small bowel and colon. The rectum is
usually defined as from the level of the anus to the sigmoid
flexure and received a dose of V30 <40%. The small bowel
loops and colon were outlined within the irradiated volume
plus a 2 cm margin and a dose of V30 <15% was given.
The source used in HDR brachytherapy was iridium-192.
A cumulative dose of 20e33.5 Gy to point A in four to seven
fractions, two fractions/week, was prescribed. The median
number of HDR brachytherapy was 6 fractions. The median
day of IMRT and HDR brachytherapy was 64 days, ranging
from 52 to 85 days.
Chemotherapy
Ninety-seven patients received concurrent weekly cisplatin
30e40 mg/m2 and a maximum of six doses of cisplatin were
given. The median cycle of weekly chemotherapy was five
cycles, ranging from one to six cycles. All patients who
received pelvic irradiation routinely received cisplatin
40 mg/m2/week. Dose modifications of 30 mg/m2/week
might be prescribed for patients if: (1) patients received
extended field irradiation; (2) Karnofsky performance
status 70; (3) age 70 years old; and (4) grade 1 or 2
hematological toxicity occurred during chemoradiotherapy.
If grade 3 or 4 hematological toxicity occurred, chemo-
therapy was held. Twenty-eight patients were treated with
two courses of cisplatin 50e75 mg/m2 day 1, plus fluoro-
uracil 500e1000 mg/m2 day 1w4, at weeks 1 and 5. Acute
gastrointestinal (GI) and hematological toxicity of CCRT
were assessed weekly using the Common Terminology
Criteria for Adverse Events (CTCAE) v3.0. Dose modifica-
tions were prescribed for subsequent cycles, based on the
acute toxicity grade. If a patient had grade 3 or 4 hema-
tological toxicity, chemotherapy was held.
Statistical analysis
The endpoints were OS, local failure-free survival (LFFS)
and disease-free survival (DFS). The OS was defined as thetime from the initial date of CCRT, to the date of death
from any cause or last follow-up. The LFFS was measured
from the initial date of CCRT, to the date of any evidence of
local recurrence or last follow-up. The DFS was calculated
from the initial date of CCRT, to the date of any evidence of
local recurrence, or distant metastasis or last follow-up.
Survival analysis was estimated using the Kaplan-Meier
method. A univariate comparison of subgroup survival
curves was performed using the log-rank test. Age,
histology, lymph node metastasis, the cumulative dose of
weekly cisplatin, pretreatment hemoglobin level and stage
were incorporated in the multivariate Cox proportional
hazard model, to estimate the hazard ratio and 95% confi-
dence intervals. The statistical analysis was performed
using SPSS software, version 10.0. A p value <0.05 was
regarded as statistically significant.
Results
Table 1 summarizes the patients’ characteristics. The
median age was 54 years, ranging from 29 to 77 years. One
hundred and five patients had biopsy-proven SCC and 20
patients had adenocarcinoma. Ninety-four patients had
clinically negative lymph nodes, and 31 patients had
Table 3 Late toxicity of IMRT with concurrent chemo-
therapy (n Z 125).
Grade GI system GU system
1 10 8
2 11 6
3 1 2
4 4 4
Total 26 20
GI Z gastrointestinal; GU Z genitourinary; IMRT Z intensity-
modulated radiotherapy.
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Of 31 patients with clinical lymph node metastasis, 13
patients were pelvic lymph node metastasis only and
received pelvic radiotherapy and 18 patients had enlarged
para-aortic lymph nodes and received extended field
radiotherapy. The cumulative dose of weekly cisplatin was
calculated and the median cumulative dose of weekly
cisplatin was 180 mg/m2. We categorized patients into
a high-dose chemotherapy group (>180 mg/m2) and a low-
dose chemotherapy group (180 mg/m2).
All patients completed the prescribed course of IMRT
and concurrent chemotherapy, plus HDR brachytherapy
boost. One hundred and eighteen patients (94.4%) had
clinical complete response after external beam radio-
therapy. Seven patients (5.6%) had persistent disease after
external beam radiotherapy of 50.4 Gy and they completed
the HDR brachytherapy course. Two (1.6%) still had residual
tumor after the whole course of IMRT and HDR brachy-
therapy and they underwent salvage radical hysterectomy.
Themedian follow-upwas 42months, ranging from 5 to 92
months. The 4-year OS, LFFS, and DFS for all patients were
73.8%, 77.9%, and 67.2%, respectively. There were no
treatment-related deaths in this study. At the end of follow-
up, 35 patients (28.0%) experienced tumor relapse. Ten
patients (8.0%) had locoregional recurrence, 12 patients
(9.6%) experienced distant metastasis, and 13 patients
(10.4%) had locoregional and distant metastasis. Of the 23
patients (18.4%) with locoregional relapse, primary site
recurrence was the most common failure pattern. Of 18
patients who underwent extended field radiotherapy, one
patient had para-aortic lymph node recurrence; of 107
patients received pelvis radiotherapy, two patients experi-
enced para-aortic lymph nodes recurrence. Among the 25
patients (20.0%) with distant metastasis, distant metastasis
sites included lung and mediastinum lymph nodes (8
patients), liver (5 patients), neck lymph nodes (3 patients),
bone (4 patients), peritoneal (5 patients), and inguinal lymph
nodes (2 patients). Of patients with distant metastasis,
chemotherapy is themainstay treatment. Of 10 patients with
local regional relapse, three underwent salvage surgery and
others received salvage radiotherapy or chemotherapy.
Acute toxicity was assessed weekly during radiotherapy
and summarized in Table 2. Four patients (3.2%) developed
grade acute GI toxicity and 29 patients (23.2%) developed
grade 3 or greater hematological toxicity. Table 3 showed
late toxicity. Five patients (4.0%) developed grade 3
chronic GI toxicity and seven patients (5.6%) developed
grade 3 genitourinary system toxicity.
Table 4 summarizes the univariate analysis. Adenocar-
cinoma was a significant prognostic factor of poor OSTable 2 Acute toxicity of IMRT with concurrent chemotherapy
Grade Nausea Vomiting Diarrhea
1 18 9 27
2 3 1 9
3 0 0 3
4 0 0 1
Total 21 10 40
IMRT Z intensity-modulated radiotherapy.(Fig. 1, p Z 0.05), LFFS (p Z 0.01) and DFS (p Z 0.006).
Patients with lymph nodes metastases at diagnosis had
worse OS (Fig. 2, pZ 0.02). The higher cumulative dose of
weekly cisplatin had better OS (Fig. 3, p Z 0.03) and ten-
ded to be associated with better LFFS (p Z 0.13) and DFS
(p Z 0.10). Advanced stage tended to have poor survival.
The 4-year OS, LFFS and DFS for stage I þ II and stage III
were 76.2% versus 70.1% (p Z 0.35), 80.4% versus 72.3%
(pZ 0.59) and 70.8% versus 60.7% (pZ 0.52), respectively.
The 4-year OS, LFFS and DFS for pretreatment hemoglobin
level 11 g/dL and pretreatment hemoglobin level <11 g/
dL were 74.6% versus 71.1% (p Z 0.94), 81.0% vs. 69.5%
(p Z 0.17) and 70.1% vs. 59.3% (p Z 0.31), respectively.
Table 5 summarizes the multivariate analysis. Adeno-
carcinoma was an independent factor of OS (HR Z 7.83;
95% CI Z 2.23e27.4; p Z 0.001), LFFS (HR Z 5.67; 95%
CI Z 1.68e19.1; p Z 0.005) and DFS (HR Z 6.47; 95%
CIZ 2.26e18.5; p < 0.001). The cumulative dose of weekly
cisplatin was an independent predictor of OS (HR Z 0.31;
95% CI Z 0.10e0.63; p Z 0.041) and higher cumulative
cisplatin dose tended to be associated with better DFS
(HR Z 0.47; 95% CI Z 0.19e1.16; p Z 0.102) and LFFS
(HR Z 0.41; 95% CI Z 0.15e1.12; p Z 0.083). The lymph
nodes metastasis was a significant predictive factor of OS
(HRZ 3.83; 95% CIZ 1.33e11.0; pZ 0.013). Pretreatment
hemoglobin level was an independent factor for local
control (HR Z 0.33; 95% CI Z 0.12e0.92; p Z 0.034).Discussion
In this article, we had a longer median follow up time than
a previous published study,8 and all patients received
uniform treatment, which consisted of IMRT with concur-
rent chemotherapy plus HDR brachytherapy.(n Z 125).
Dermatitis Leukopenia Anemia
8 21 18
5 39 15
3 28 0
0 1 1
16 89 34
Table 4 Univariate analysis for OS, LFFS and DFS.
Parameter Four-year rate (%)
OS LFFS DFS
Age
<54 y (n Z 58) 79.7 76.9 69.4
54 y (n Z 67) 67.9 78.9 65.1
p Z 0.08 p Z 0.66 p Z 0.71
Histology
Adenocarcinoma
(n Z 20)
47.2 55.4 45.3
SCC (n Z 105) 77.4 83.9 71.3
p Z 0.05 p Z 0.01 p Z 0.006
Stage
I þ II (n Z 76) 76.2 80.4 70.8
III (n Z 49) 70.1 72.3 60.7
p Z 0.35 0.59 0.52
Lymph node metastasis
Negative (n Z 94) 79.1 78.0 70.0
Positive (n Z 31) 56.4 78.7 58.1
p Z 0.02 p Z 0.71 p Z 0.13
Pretreatment hemoglobin level
11 g/dL (n Z 89) 74.6 81.0 70.1
<11 g/dL (n Z 36) 71.1 69.5 59.3
p Z 0.94 p Z 0.17 p Z 0.31
Chemotherapy
Monthly (n Z 28) 78.3 86.3 70.6
Weekly (n Z 97) 71.8 75.5 66.7
p Z 0.54 p Z 0.19 p Z 0.67
Cumulative dose of weekly cisplatin
180 mg/m2
(n Z 50)
60.5 66.0 55.7
>180 mg/m2
(n Z 47)
81.9 84.7 77.2
p Z 0.03 p Z 0.13 p Z 0.10
Serum SCC-Ag
2 ng/mL (n Z 29) 68.8 75.8 63.8
>2 ng/mL (n Z 76) 80.8 84.1 74.1
p Z 0.35 p Z 0.33 p Z 0.29
DFS Z disease free survival; LFFS Z local failure free survival;
OS Z overall survival; SCC Z squamous cell carcinoma; serum
SCC-Ag Z serum squamous cell carcinoma antigen.
Figure 1 Overall survival (OS) according to histology.
Figure 2 Overall survival (OS) according to lymph nodes
metastasis.
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therapy are that IMRT has more conformal dose distribution
and high dose gradients. These differences have potential
benefits, including a higher dose to target and lower dose to
critical organ, and may diminish acute and late toxicity.
The theoretical drawbacks of IMRT are a longer treatment
time, the possibility of organ motions, and the possibility of
an inadequate coverage of targets. Patient immobilization,
repeat check-up of patient positions and cautious target
and critical organ delineation are important in IMRT treat-
ment planning.
Five randomized trials1e5 treated patients with
conventional radiotherapy. They showed that the local
regional recurrence rate was 19e20%. Our results demon-
strated local a regional recurrence rate of 18.4%, after 4
years follow up. IMRT with delineating adequate target
volume, and using adequate margins, could achieve
compatible outcomes with conventional radiotherapy.
To our best knowledge, there were limited studies
focused on the effect of the cumulative cisplatin dose.Figure 3 Overall survival (OS) according to cumulative dose
of cisplatin.
Table 5 Multivariate analysis for OS, LFFS, DFS.
Variables HR (95% CI) p
OS
Age (54 y vs. <54 y) 1.68 (0.58e4.86) 0.336
Histology (adenocarcinoma vs. SCC) 7.83 (2.23e27.4) 0.001
Lymph node metastasis (positive vs. negative) 3.83 (1.33e11.0) 0.013
Cumulative dose of weekly cisplatin (>180 mg/m2 vs. 180 mg/m2) 0.31 (0.10e0.96) 0.041
Pretreatment hemoglobin level (g/dL) (11 vs. <11) 1.33 (0.44e4.04) 0.616
Stage (III vs. I þ II) 1.22 (0.44e3.42) 0.701
LFFS
Age (54 y vs. <54 y) 1.02 (0.37e2.88) 0.965
Histology (adenocarcinoma vs. SCC) 5.67 (1.68e19.1) 0.005
Lymph node metastasis (positive vs. negative) 0.97 (0.32e2.91) 0.951
Cumulative dose of weekly cisplatin (>180 mg/m2 vs. 180 mg/m2) 0.41 (0.15e1.12) 0.083
Pretreatment hemoglobin level (11 vs. <11) 0.33 (0.12e0.92) 0.034
Stage (III vs. I þ II) 1.20 (0.45e3.23) 0.721
DFS
Age (54 y vs. <54 y) 1.11 (0.45e2.74) 0.819
Histology (adenocarcinoma vs. SCC) 6.47 (2.26e18.5) <0.001
Lymph node metastasis (positive vs. negative) 1.87 (0.75e4.64) 0.180
Cumulative dose of weekly cisplatin (>180 mg/m2 vs. 180 mg/m2) 0.47 (0.19e1.16) 0.102
Pretreatment hemoglobin level (11 vs. <11) 0.66 (0.26e1.66) 0.374
Stage (III vs. I þ II) 1.37 (0.57e3.31) 0.481
DFS Z disease free survival; LFFS Z local failure free survival; OS Z overall survival; SCC Z squamous cell carcinoma.
236 C.-C. Chen et al.Torres et al9 collected 302 patients with cervical cancer and
showed that a cisplatin dose >200 mg/m2 was an inde-
pendent predictor of improved disease-specific survival.
Our study used the median cumulative dose of weekly
cisplatin as a cutoff point and found that a higher cumu-
lative dose of weekly cisplatin (>180 mg/m2) had a better
OS and tended to be correlated with good outcomes in
terms of DFS and LFFS.
Eifel et al10 analyzed 229 patients with stage IB adeno-
carcinoma of the cervix. The 5-year survival rate was 72%
versus 81% for SCC. The incidence of pelvic recurrence was
similar (17% for adenocarcinoma and 13% for SCC).
However, distant metastases were more frequent in
patients with adenocarcinoma (37% vs. 21%; p < 0.01). The
4-year OS, LFFS and DFS rates in our patients, for adeno-
carcinoma and SCC, were 47.2% versus 77.4% (p Z 0.05),
55.4% versus 83.9% (p Z 0.01) and 45.3% versus 71.9%
(p Z 0.006), respectively.
Yamashita et al11 reported that pelvic lymph nodes
metastases and para-aortic lymph nodes metastases
affected OS. Grigiene R et al12 noted that a lymph node
>10 mm on CT was significantly correlated with OS
(p Z 0.03) and local control (p Z 0.036). In this study, we
assessed lymph nodes status with CT scan. Our data showed
that lymph nodes status affected the OS (p Z 0.02).
Esthappan et al13 used PET/CT in patients with positive
lymph nodes and treated patients with IMRT. PET/CTshowed
the potential to evaluate lymph nodes status, which could
therefore allow for a more aggressive treatment of cervical
cancer. In our institution, a PET scan was elective for
patients with suspicion of lymph nodemetastasis. If PETscan
showed a positive finding over lymph nodes, a higher radia-
tion dose was given to the positive lymph nodes.Haensgen et al14 found that advanced stage had an
effect on survival. In their study, FIGO stage IIIB was worse
than FIGO stage IB and IIB. In our series, we showed that
FIGO stage I þ II tended to have better OS, LFFS and DFS
than FIGO stage III, but the difference was not significant.
The difference was not statistically significantly different,
due to small number of patients of each FIGO stage.
Haensgen14 et al found that a pretreatment hemoglobin
level 11 g/dL had a better 3-year survival. In this study,
pretreatment hemoglobin level was an independent factor
of LFFS. If the hemoglobin level was lower than 10 g/dL
during the treatment course, a blood transfusion was
arranged. Blood transfusion may affect the hemoglobin
level and diminish the pretreatment hemoglobin level
effect.
Dattoli15 et al showed that patients 40 years old had
a poorer 5-year survival than patients > 40 years old. In our
study, only seven patients were 40 years old. We used
median age as a cutoff point and categorized patients into
two groups. Our results showed that survival was not
significantly different in these groups.
There were 105 patients with histologically proven SCC
in this study. Seventy-six (72.3%) of these had elevated
serum SCC. Previous studies16e20 showed that the correla-
tion between serum SCC and survival was controversial.
Volgger et al16 found that SCC-Ag < 2 ng/mL had a better
OS (p < 0.001). Juang et al20 used 1.5 as a cutoff value and
revealed that serum SCC was a predictor of prognosis, but
this did not reach statistically significant in multivariate
analysis. Our data showed that the cutoff value 2 of serum
SCC level had no significant difference on OS, DFS and LFFS.
This retrospective study had several limitations. First,
the small number of patients limited our ability to perform
Prognostic factors for cervical cancer patients 237multiple adjustments for potential confounders and the
power of our analysis to detect small differences. A large,
multi-institutional study is needed to identify the prog-
nostic factors of locally advanced cervical cancer. Second,
a more precise system, such as image guided radiotherapy,
is needed to deliver treatment planning.
Conclusion
Adenocarcinoma and initial lymph nodes metastases were
poor prognostic factors for patients with locally advanced
cervical cancer. Lower pretreatment hemoglobin levels had
poorer local control. Chemotherapy, with a high cumulative
dose of cisplatin, tended to be associated with better
survival.
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